"With the full integration of our own production site, we are completing an important milestone for our ambitious growth targets," said Managing Director and CFO Gerhard Mayer. "Together with the Polish management, we will develop the site into a center of excellence for manufacturing and development of oral dosage forms for the Wörwag Pharma group."
Wörwag Pharma is investing primarily in the expansion of its global product portfolio and the development of new markets. With the full integration of Wörwag Pharma Operations, the company is securing the necessary production capacities in addition to its existing partnerships with suppliers. Wörwag started to transfer the first products, guarantees a reliable supply chain and provides its customers with continuous access to high-quality products.
“Over the next four years significant investments will be seen in connection with the transfer of 25 Wörwag Pharma products. This is one of the biggest tech-transfer, investment and growth initiative in the industry of our size”, says Irmgard Becker, Director Global Technical Operations.
“Our team is pleased to complete this final step towards the integration into the structure of the family owned Wörwag Group”, says Joanna Nidecka, Managing Director and member of the board.
The modern building complex for production and development offers the opportunity to create capacity for further growth. The location is logistically favorable for supplying the core markets in Eastern Europe. In addition, this operation site brings further expertise to the company to expand the product portfolio by developing its own innovations.